These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 3293339

  • 1. Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes.
    Glaser B, Leibovich G, Nesher R, Hartling S, Binder C, Cerasi E.
    Acta Endocrinol (Copenh); 1988 Jul; 118(3):365-73. PubMed ID: 3293339
    [Abstract] [Full Text] [Related]

  • 2. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
    van der Wal PS, Draeger KE, van Iperen AM, Martini C, Aarsen M, Heine RJ.
    Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
    [Abstract] [Full Text] [Related]

  • 3. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function.
    Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, Hu G, Weng J.
    Diabetes Care; 2004 Nov; 27(11):2597-602. PubMed ID: 15504992
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
    Vilsbøll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ.
    Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.
    Abbink EJ, van der Wal PS, Sweep CG, Smits P, Tack CJ.
    Diabetes Metab Res Rev; 2004 Jun; 20(6):466-71. PubMed ID: 15386823
    [Abstract] [Full Text] [Related]

  • 8. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
    Yu JG, Kruszynska YT, Mulford MI, Olefsky JM.
    Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
    [Abstract] [Full Text] [Related]

  • 9. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
    Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC.
    Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance.
    Byrne MM, Gliem K, Wank U, Arnold R, Katschinski M, Polonsky KS, Göke B.
    Diabetes; 1998 Aug; 47(8):1259-65. PubMed ID: 9703326
    [Abstract] [Full Text] [Related]

  • 12. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE, Matthews DR.
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [Abstract] [Full Text] [Related]

  • 13. Progressive deterioration of beta-cell function in nonobese type 2 diabetic subjects. Postprandial plasma C-peptide level is an indication of insulin dependency.
    Prando R, Odetti P, Melga P, Giusti R, Ciuchi E, Cheli V.
    Diabetes Metab; 1996 Jun; 22(3):185-91. PubMed ID: 8697306
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.
    Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA.
    Diabetes Care; 2003 Mar; 26(3):791-8. PubMed ID: 12610039
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Evidence against a rate-limiting role of proinsulin processing for maximal insulin secretion in subjects with impaired glucose tolerance and beta-cell dysfunction.
    Stumvoll M, Fritsche A, Stefan N, Hardt E, Häring H.
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1235-9. PubMed ID: 11238514
    [Abstract] [Full Text] [Related]

  • 18. The plasma C-peptide and insulin responses to stimulation with intravenous glucagon and a mixed meal in well-controlled type 2 (non-insulin-dependent) diabetes mellitus: dependency on acutely established hyperglycaemia.
    Gjessing HJ, Reinholdt B, Pedersen O.
    Diabetologia; 1989 Dec; 32(12):858-63. PubMed ID: 2693165
    [Abstract] [Full Text] [Related]

  • 19. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
    Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O.
    Diabetes; 2004 May; 53(5):1187-94. PubMed ID: 15111485
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.